Pls find enclosed Financial Results for the quarter ended 30.09.2026.

Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com 30th October 2026 BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot no. Dalal Street, C/1, G Block, Bandra Kurla Complex, Mumbai – 400001 Bandra (East), Mumbai – 400 051 Scrip Code: BSE – AJANTPHARM 532331 Scrip Code: NSE AJANTPHARM EQ Sub.: Outcome of the Board Meeting Dear Sir/Madam, At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial Results for the quarter and half year ended 30th September 2026. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the second quarter and half year ended 30th September 2026; ii. Unaudited Consolidated Financial Results for the second quarter and half year ended 30th September 2026; iii. Limited Review Report from Auditors M/s. B S R & Co. LLP on the Unaudited Consolidated Financial Results for the second quarter and half year ended 30th September 2026; iv. Unaudited Standalone Financial Results for the second quarter and half year ended 30th September 2026; v. Limited Review Report from Auditors M/s. B S R & Co. LLP on the Unaudited Standalone Financial Results for the second quarter and half year ended 30th September 2026; vi. Investor presentation. Meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 12:50 p.m. Kindly take the above on your records. Thanking You, Yours faithfully, GAURANG SHAH Sr. VP - Legal & Company Secretary Encl.: a/a Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com Press Release Revenue up by 33% and PAT up by 49% (2nd Quarter FY 2027 Consolidated Results) Mumbai, 30th October, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 2nd quarter, and half year ended 30th September 2026. Q2 FY 2027 performance highlights (compared to Q2 FY 2026): • Revenue from operations at Rs. 1,794 cr. against Rs. 1,354 cr.; up 33%. • Adjusted EBITDA (excluding forex loss) at Rs. 543 cr. & 30% against Rs. 369 cr., up 47%. • Profit after tax at Rs. 388 cr. against Rs. 260 cr.; PAT at 22%; up 49%. H1 FY 2027 performance highlights (compared to H1 FY 2026): • Revenue from operations at Rs. 3,420 cr. against Rs. 2,656 cr.; up 29%. • Adjusted EBITDA (excluding forex loss) at Rs. 997 cr. & 29% against Rs. 745 cr., up 34%. • Profit after tax at Rs. 722 cr. against Rs. 516 cr.; PAT at 21%; up 40%. • ROCE stood at a healthy level of 41% and RONW at 31%. Segment wise performance: (Rs. cr.) Q2 H1 Markets Gwth% Gwth% FY 2026 FY 2027 FY 2026 FY 2027 Branded Generics India ₹ 432 ₹ 504 16% ₹ 841 ₹ 1,013 20% Asia ₹ 310 ₹ 366 18% ₹ 614 ₹ 621 1% Africa ₹ 221 ₹ 312 41% ₹ 449 ₹ 607 35% Sub-Total ₹ 963 ₹ 1,182 23% ₹ 1,904 ₹ 2,241 18% US Generic ₹ 344 ₹ 484 41% ₹ 653 ₹ 971 49% Africa Institution ₹ 32 ₹ 116 259% ₹ 71 ₹ 187 164% Total ₹ 1,339 ₹ 1,782 33% ₹ 2,628 ₹ 3,399 29% As per IQVIA MAT September 2026, our India branded generic performance exceeded IPM growth by 27%. The higher growth came from new launches, which exceeded IPM by 70% & volumes, which exceeded IPM by 18%. Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com India branded generic segment wise performance as per IQVIA MAT September 2026 against IPM is as below: Growth % Therapy IPM Ajanta Cardiology 17% 13% Ophthalmology 12% 18% Dermatology 11% 14% Pain Management 13% 16% Overall 13% 17% Though our Cardiology growth looks lower than IPM as per IQVIA due to some anomaly in the working, our internal growth is at par with the IPM. ANDA status as at the end of H1 FY 2027 is as below: Particulars H1 FY 2027 Filed 1 Approval received 4 Launched 3 Total ANDA's commercialized 52 Awaiting approval with US FDA 17 Tentative approval 5 R&D expense: (Rs. cr.) % to Particulars FY 2026 FY 2027 Revenue Q2 ₹ 63 ₹ 72 4% H1 ₹ 119 ₹ 138 4% About Ajanta Pharma Limited Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 34+ countries. Many of company’s products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa. Company’s state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India. For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%. Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com Earnings Conference Call The Company will host an Earnings Conference Call at 16:00 hrs. IST (18:30 hrs. SST/HKT, 10:30 hrs. GMT, 06:30 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com. Dial-in Information Date and Time October 30, 2026 at 16:00 – 17:00 hrs IST 18:30 – 19:30 hrs SST/HKT 10:30 – 11:30 hrs GMT 06:30 – 07:30 hrs US ET Dial-in Numbers Diamond pass link for faster access Click here to register Universal Access Primary Access: (+91 22 6280 1542) (+91 22 7115 8372) International Toll Free USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 For convenience and faster connectivity to the conference, kindly follow the below steps: 1. Register through the Diamond pass link. 2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time. 3. Dial the ‘conference Dial-in number’ you will receive on your email. 4. On system prompt dial the PASSCODE followed by # key. 5. On system prompt enter the PIN followed by # key. 6. If the line gets disconnected, you need to dial the ‘conference dial-in number’ again and follow the necessary steps. Playback of Earnings Conference Call audio: Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com). For more details visit www.ajantapharma.com For regular updates follow us on x.com – https://x.com/AjantaPharmaLtd For specific queries, contact: Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331 Corporate Identity Number (CIN): L24230MH1979PLC022059 Safe Harbour Statement Corporate Identity Number - L24230MH1979PLC022059 Greot Ajanta Pharma Limited Plqce aianta pharma Ajanta Tower, 54-A, [I V Road, +91 22 6060 9000 to E Work" Chakala, Andheri (E), aplfinance@ajantapharma.com Mumbai - 400 093, lndia W wwwalantapharma.com Ccrtified Statemcnt of Consolidateal Unaudited Financial Results for the quarter and six months ended 30 September 2026 3GSeo-26 3GJ!n 26 3GSeD 25 30 Seo 26 30 Seo-25 Revenue rrom operations 1,7 .16 1,625.96 1,353 73 3,12012 2.656.36 5,452 a5 Other in@me (Rcrernolo 4) 37.39 70.90 59 34 108 29 85.67 1t2 07 1,831.55 1,696.86 1,413.07 3.528 41 2,742.05 5,624.93 Cosl ol malerials consumed 344.97 296.51 217.60 645 4a 424.@ 916.51 Purchas€s ol slocl'in-trade 80.89 66 92 53 26 117.81 104 69 229.79 Changes in invenlories ol linish€d goods, wo*-in prol [Showing first 8,000 characters — download PDF for full document]